You’ve hit your search limit
Start your free trial to keep exploring full traffic and performance insights.
Get Started- Home
- Free App Analytics
- cubeCONSENT 3.0 - For Site INV
cubeCONSENT 3.0 - For Site INV app analytics for May 18
cubeCONSENT 3.0 - For Site INV
- CRScube Inc.
- Apple App Store
- Free
- Medical
'cubeCONSENT 3.0® - For Site INV' is a mobile app to access the investigator portal for CRScube's eConsent solution 'cubeCONSENT 3.0®'.
App Features:
- Manage all aspects of your study's informed consent process electronically on your mobile phone.
- Create subject accounts and assign consent forms.
- View the status of assigned consent forms in real time.
- Conduct investigator signatures electronically for consent forms that have been signed by subjects.
- Upload consents forms that have been signed offline.
- Seamless integration with cubeCDMS®.
CRScube:
CRScube provides a comprehensive suite of eClinical solutions to CROs, Biotech, Pharmaceutical, Academic, and Non-Profit organizations globally. We are dedicated to providing the latest eClinical technology that is fast, flexible, and easy-to-use to streamline end-to-end operations for Phase I-IV, medical device, and Investigator-Initiated Trials.
Store Rank
The Store Rank is based on multiple parameters set by Google and Apple.
All Categories in
United States--
Medical in
United States--
Create an account to see avg.monthly downloadsContact us
cubeCONSENT 3.0 - For Site INV Ranking Stats Over Time
Similarweb's Usage Rank & Apple App Store Rank for cubeCONSENT 3.0 - For Site INV
Rank
No Data Available
cubeCONSENT 3.0 - For Site INV Ranking by Country
Counties in which cubeCONSENT 3.0 - For Site INV has the highest ranking in its main categories
No Data to Display
Top Competitors & Alternative Apps
Apps with a high probability of being used by the same users, from the same store.
DrPro Clinic
DRPRO APP LLP
iMedicine Review Lite
Shahid Babar
Patient Link
Clinflash Healthcare Technology (Jiaxing) Co.,Ltd
Physica
Xreality Solutions Private Limited
May 18, 2026